Skip to the chapter Tirzepatide Finding someone to prescribe tirzepatide Chapter index - First check Find a route - Fact check Know the medicine - Question list Prepare for care - Cost checklist Untangle payment Fact check · The medicine # Know what the medicine claim means. Start with the exact medicine name. Then check what the source actually says about it. Your medicine check - Name the medicine - Check approved uses and pharmacy-made versions - Read the source ## Same ingredient. Different approved uses. The U.S. Food and Drug Administration (FDA) checks medicines before it approves them for specific health problems. As of September 2026, tirzepatide (Mounjaro) is approved for type 2 diabetes, a condition involving high blood sugar. Its label, the official instructions and warnings, also covers reducing major heart risks in adults with type 2 diabetes who are at high risk. Mounjaro’s label does not approve it for weight loss (as of September 2026). Source: Mounjaro label, National Library of Medicine ↗ Tirzepatide (Zepbound) has approval for adult weight management alongside diet and physical activity, as of September 2026. That use covers adults with obesity, or with overweight plus a health problem linked to weight. As of September 2026, it also covers adults with obesity whose obstructive sleep apnea is moderate to severe. Obstructive sleep apnea means repeated blocks in breathing during sleep. Source: Zepbound label, National Library of Medicine ↗ Pause at this word ## What does “compounded” mean? Compounding means a pharmacist or doctor mixes a medicine for a particular patient instead of dispensing a ready-made medicine from a drug company. As of September 2026, compounded medicines are not approved by the FDA. Before these medicines are sold, the FDA does not review how safe they are, their quality or how well they work. As of September 2026, the FDA says compounding can help a person with medical needs an approved medicine cannot meet. For example, a pharmacy might leave out a dye that a patient is allergic to. Source: FDA’s questions and answers on compounding ↗ Read the exact claim, then its source. ## The shortage story has changed As of September 2026, the FDA no longer listed tirzepatide as a medicine in short supply across the country. The FDA’s extra time for pharmacies to stop tirzepatide copies that broke shortage-related rules had ended by September 2026. A medicine does not join the national shortage list simply because one pharmacy has run out. Source: FDA’s dated compounding policy updates ↗ As of September 2026, ordinary pharmacies cannot regularly make tirzepatide that is essentially the same as a medicine already sold by a drug company. A pharmacy may change a named patient’s medicine if the person prescribing it finds that the alteration makes a significant difference for that patient. This means a meaningful difference for the patient, not just a lower price, as of September 2026. A state-licensed pharmacy and a valid prescription for that patient are also required. Even with a medical need, the preparation must meet all the legal requirements for pharmacy-made medicines. Source: federal law on pharmacy-made copies ↗ Why can’t an approved medicine meet my needs, and what rules allow this pharmacy to make my prescription? A claim worth opening ## Check a common mix-up Open a question to reveal what the evidence says. How does pharmacy-made tirzepatide differ from a brand-name copy? + An FDA-approved copy of a brand-name medicine is called a generic. As of September 2026, tirzepatide has no approved generic, and a pharmacy-made version is not one. Source: FDA drug application records ↗ Does a small medicine bottle, called a vial, mean it is pharmacy-made? + No. As of September 2026, tirzepatide (Zepbound) also comes in FDA-approved small bottles called vials. Check who made the medicine; the bottle alone cannot tell you. Source: Zepbound label, National Library of Medicine ↗ Does “research use” make it a treatment option? + FDA warns against unapproved tirzepatide sold for human use under research labels because its quality is unknown and it may cause harm (as of September 2026). Source: FDA’s concerns about weight medicines outside the approval process ↗ ## What did a weight trial find? With tirzepatide, the SURMOUNT-1 study recorded an average loss of about 15% to 21% of starting weight over 72 weeks. These results came from adults without diabetes. The amount of medicine in the study’s shots affected the average weight loss. People given shots without the study medicine lost about 3% of their starting weight on average. The drug maker supported the trial, which included regular visits and help with daily habits. A trial average is not a promised result for an individual. Source: weight trial published in the New England Journal of Medicine ↗ Carry this forward ## Know the product before comparing the claims. Next chapter: prepare your questions → This guide helps you find the next question on the way to tirzepatide care; it is no clinic and sells no medicine. Back to the first check Read this chapter as text Full text edition Room for questions. Time to think.